iX Biopharma Signs Exclusive License Agreement For Wafermine And Other Sublingual Ketamine Wafer ProductsPRNewsWire • 11/29/21
Seelos Therapeutics Announces Acquisition of an Exclusive License of iX Biopharma's Proprietary Wafer-Based Delivery Platform for Sublingual KetaminePRNewsWire • 11/24/21
Seelos Therapeutics Raises $20 Million in Private Placement of Senior Secured Convertible NotePRNewsWire • 11/24/21
Seelos Therapeutics To Test Trehalose In Patients With Rare Movement Control DisorderBenzinga • 11/08/21
Seelos Therapeutics Announces FDA Acceptance of Investigational New Drug Application and Grant of Fast Track Designation for SLS-005 (IV Trehalose) for the Treatment of Spinocerebellar AtaxiaPRNewsWire • 11/08/21
Why This Seelos Therapeutics Analyst Is Turning Bullish On Potential Trial ResultsBenzinga • 09/27/21
Seelos Therapeutics Shares Gain On FDA Approval To Add SLS-005 Regimen In HEALEY ALS TrialBenzinga • 09/21/21
Seelos Therapeutics Announces Appointment of Margaret Dalesandro to the Board of DirectorsPRNewsWire • 09/02/21